Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline

Q. Chen, F. Chen, C. Long, Y. Zhu, Y. Jiang, Z. Zhu, J. Lu, X. Zhang, Z. Nedelska, J. Hort, B. Zhang

. 2023 ; 15 (1) : 86. [pub] 20230425

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011711

BACKGROUND: Subjective cognitive decline (SCD) may serve as a symptomatic indicator for preclinical Alzheimer's disease; however, SCD is a heterogeneous entity regarding clinical progression. We aimed to investigate whether spatial navigation could reveal subcortical structural alterations and the risk of progression to objective cognitive impairment in SCD individuals. METHODS: One hundred and eighty participants were enrolled: those with SCD (n = 80), normal controls (NCs, n = 77), and mild cognitive impairment (MCI, n = 23). SCD participants were further divided into the SCD-good (G-SCD, n = 40) group and the SCD-bad (B-SCD, n = 40) group according to their spatial navigation performance. Volumes of subcortical structures were calculated and compared among the four groups, including basal forebrain, thalamus, caudate, putamen, pallidum, hippocampus, amygdala, and accumbens. Topological properties of the subcortical structural covariance network were also calculated. With an interval of 1.5 years ± 12 months of follow-up, the progression rate to MCI was compared between the G-SCD and B-SCD groups. RESULTS: Volumes of the basal forebrain, the right hippocampus, and their respective subfields differed significantly among the four groups (p < 0.05, false discovery rate corrected). The B-SCD group showed lower volumes in the basal forebrain than the G-SCD group, especially in the Ch4p and Ch4a-i subfields. Furthermore, the structural covariance network of the basal forebrain and right hippocampal subfields showed that the B-SCD group had a larger Lambda than the G-SCD group, which suggested weakened network integration in the B-SCD group. At follow-up, the B-SCD group had a significantly higher conversion rate to MCI than the G-SCD group. CONCLUSION: Compared to SCD participants with good spatial navigation performance, SCD participants with bad performance showed lower volumes in the basal forebrain, a reorganized structural covariance network of subcortical nuclei, and an increased risk of progression to MCI. Our findings indicated that spatial navigation may have great potential to identify SCD subjects at higher risk of clinical progression, which may contribute to making more precise clinical decisions for SCD individuals who seek medical help.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011711
003      
CZ-PrNML
005      
20230801133253.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13195-023-01233-6 $2 doi
035    __
$a (PubMed)37098612
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chen, Qian $u Department of Radiology, Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, China $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
245    10
$a Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline / $c Q. Chen, F. Chen, C. Long, Y. Zhu, Y. Jiang, Z. Zhu, J. Lu, X. Zhang, Z. Nedelska, J. Hort, B. Zhang
520    9_
$a BACKGROUND: Subjective cognitive decline (SCD) may serve as a symptomatic indicator for preclinical Alzheimer's disease; however, SCD is a heterogeneous entity regarding clinical progression. We aimed to investigate whether spatial navigation could reveal subcortical structural alterations and the risk of progression to objective cognitive impairment in SCD individuals. METHODS: One hundred and eighty participants were enrolled: those with SCD (n = 80), normal controls (NCs, n = 77), and mild cognitive impairment (MCI, n = 23). SCD participants were further divided into the SCD-good (G-SCD, n = 40) group and the SCD-bad (B-SCD, n = 40) group according to their spatial navigation performance. Volumes of subcortical structures were calculated and compared among the four groups, including basal forebrain, thalamus, caudate, putamen, pallidum, hippocampus, amygdala, and accumbens. Topological properties of the subcortical structural covariance network were also calculated. With an interval of 1.5 years ± 12 months of follow-up, the progression rate to MCI was compared between the G-SCD and B-SCD groups. RESULTS: Volumes of the basal forebrain, the right hippocampus, and their respective subfields differed significantly among the four groups (p < 0.05, false discovery rate corrected). The B-SCD group showed lower volumes in the basal forebrain than the G-SCD group, especially in the Ch4p and Ch4a-i subfields. Furthermore, the structural covariance network of the basal forebrain and right hippocampal subfields showed that the B-SCD group had a larger Lambda than the G-SCD group, which suggested weakened network integration in the B-SCD group. At follow-up, the B-SCD group had a significantly higher conversion rate to MCI than the G-SCD group. CONCLUSION: Compared to SCD participants with good spatial navigation performance, SCD participants with bad performance showed lower volumes in the basal forebrain, a reorganized structural covariance network of subcortical nuclei, and an increased risk of progression to MCI. Our findings indicated that spatial navigation may have great potential to identify SCD subjects at higher risk of clinical progression, which may contribute to making more precise clinical decisions for SCD individuals who seek medical help.
650    _2
$a lidé $7 D006801
650    12
$a prostorová navigace $7 D065854
650    _2
$a neuropsychologické testy $7 D009483
650    12
$a Alzheimerova nemoc $x komplikace $7 D000544
650    12
$a kognitivní dysfunkce $x psychologie $7 D060825
650    _2
$a progrese nemoci $7 D018450
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chen, Futao $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
700    1_
$a Long, Cong $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
700    1_
$a Zhu, Yajing $u Department of Radiology, Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, China $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
700    1_
$a Jiang, Yaoxian $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
700    1_
$a Zhu, Zhengyang $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
700    1_
$a Lu, Jiaming $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
700    1_
$a Zhang, Xin $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
700    1_
$a Nedelska, Zuzana $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czechia
700    1_
$a Hort, Jakub $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czechia
700    1_
$a Zhang, Bing $u Department of Radiology, Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, China. zhangbing_nanjing@nju.edu.cn $u Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China. zhangbing_nanjing@nju.edu.cn $u Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. zhangbing_nanjing@nju.edu.cn $u Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. zhangbing_nanjing@nju.edu.cn $u Jiangsu Key Laboratory of Molecular Medicine, Nanjing, China. zhangbing_nanjing@nju.edu.cn $u Institute of Brain Science, Nanjing University, Nanjing, China. zhangbing_nanjing@nju.edu.cn
773    0_
$w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 15, č. 1 (2023), s. 86
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37098612 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133250 $b ABA008
999    __
$a ok $b bmc $g 1963885 $s 1197976
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 1 $d 86 $e 20230425 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options